Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1962 1
1965 1
1969 1
1974 1
1975 2
1976 3
1977 2
1978 4
1979 8
1980 4
1981 6
1982 1
1983 16
1984 4
1985 18
1986 11
1987 11
1988 16
1989 12
1990 17
1991 19
1992 24
1993 35
1994 30
1995 26
1996 38
1997 40
1998 36
1999 38
2000 44
2001 66
2002 80
2003 103
2004 143
2005 202
2006 242
2007 284
2008 324
2009 421
2010 498
2011 559
2012 640
2013 724
2014 763
2015 855
2016 946
2017 950
2018 1190
2019 1281
2020 1611
2021 1871
2022 2262
2023 2255
2024 2477
2025 2538
2026 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,289 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
Rischin D, Porceddu S, Day F, Brungs DP, Christie H, Jackson JE, Stein BN, Su YB, Ladwa R, Adams G, Bowyer SE, Otty Z, Yamazaki N, Bossi P, Challapalli A, Hauschild A, Lim AM, Patel VA, Walker JL, De Liz Vassen Schurmann M, Queirolo P, Cañueto J, Ferreira da Silva FA, Stratigos A, Guminski A, Lin C, Damian F, Flatz L, Taylor AE, Carr DR, Harris S, Kirtbaya D, Quereux G, Rutkowski P, Basset-Seguin N, Khushalani NI, Robert C, Ju H, Joseph C, Bansal S, Chen CI, Seebach F, Yoo SY, Lowy I, Goncalves P, Fury MG; C-POST Trial Investigators. Rischin D, et al. Among authors: su yb. N Engl J Med. 2025 Aug 21;393(8):774-785. doi: 10.1056/NEJMoa2502449. Epub 2025 May 31. N Engl J Med. 2025. PMID: 40454639 Clinical Trial.
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Jin ZC, Chen JJ, Zhu XL, Duan XH, Xin YJ, Zhong BY, Chen JZ, Tie J, Zhu KS, Zhang L, Huang M, Piao MJ, Li X, Shi HB, Liu RB, Xu AB, Ji F, Wu JB, Shao GL, Li HL, Huang MS, Peng ZY, Ji JS, Yuan CW, Liu XF, Hu ZC, Yang WZ, Yin GW, Huang JH, Ge NJ, Qi X, Zhao Y, Zhou JW, Xu GH, Tu Q, Lin HL, Zhang YJ, Jiang H, Shao HB, Su YJ, Chen TS, Shi BQ, Zhou X, Zhao HT, Zhu HD, Ren ZG, Teng GJ; CHANCE2201 Investigators. Jin ZC, et al. Among authors: su yj. EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745965 Free PMC article.
Miniaturized chaos-assisted Spectrometer.
Zhang Y, Xu C, Zhao Z, Su Y, Guo X. Zhang Y, et al. Among authors: su y. Light Sci Appl. 2025 Sep 18;14(1):331. doi: 10.1038/s41377-025-01984-x. Light Sci Appl. 2025. PMID: 40968121 Free PMC article.
SLC39A8-mediated zinc dyshomeostasis potentiates kidney disease.
Cai Z, Wu X, Wang T, Song Z, Ni P, Zhong M, Su Y, Xie E, Sun S, Lin Y, Min J, Wang F. Cai Z, et al. Among authors: su y. Proc Natl Acad Sci U S A. 2025 Sep 23;122(38):e2426352122. doi: 10.1073/pnas.2426352122. Epub 2025 Sep 16. Proc Natl Acad Sci U S A. 2025. PMID: 40956895
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations.
Lin GW, Xu C, Chen K, Huang HQ, Chen J, Song B, Chan JKC, Li W, Liu W, Shih LY, Chuang WY, Kim WS, Tan W, Peng RJ, Laurensia Y, Cheah DMZ, Huang D, Cheng CL, Su YJ, Tan SY, Ng SB, Tang TPL, Han K, Wang VY, Jia WH, Pei Z, Li YJ, Gao S, Shi Y, Hu Z, Zhang F, Zhang B, Zeng YX, Shen H, He L, Ong CK, Lim ST, Chanock S, Kwong YL, Lin D, Rothman N, Khor CC, Lan Q, Bei JX; International NKTCL Working Group. Lin GW, et al. Among authors: su yj. Lancet Oncol. 2020 Feb;21(2):306-316. doi: 10.1016/S1470-2045(19)30799-5. Epub 2019 Dec 23. Lancet Oncol. 2020. PMID: 31879220
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration.
Lin YJ, Ou DL, Su YY, Hsu CL, Hsiao CF, Ko BS, Chen SC, Wang HW, Wang JH, Wu YM, Jeng YM, Lee WC, Chou SC, Chen TW, Chiu CF, Shiuan Lin Jr, Hsieh CH, Lee CC, Shen YS, Cheng AL, Chen LT, Hsu C. Lin YJ, et al. Among authors: su yy. J Hepatol. 2025 Sep 17:S0168-8278(25)02471-7. doi: 10.1016/j.jhep.2025.08.035. Online ahead of print. J Hepatol. 2025. PMID: 40972843 Free article.
21,289 results
You have reached the last available page of results. Please see the User Guide for more information.